Multifunctional actions of vanadium compounds on insulin signaling pathways: Evidence for preferential enhancement of metabolic versus mitogenic effects

Molecular and Cellular Biochemistry

Volumn 182, Issue 1-2, 1998, Pages 109-119

  Fantus, I George ^a   Tsiani, Evangelia ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Insulin action; L6 myocytes; Tyrosine kinase phosphatase; Vanadium compounds

Indexed keywords

AMINO ACID; GLUCOSE; INSULIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; VANADIUM DERIVATIVE;

AMINO ACID TRANSPORT; ARTICLE; CELL PROLIFERATION; DIABETES MELLITUS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLISM; MITOGENESIS; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INSULIN; MITOGENS; MITOSIS; SIGNAL TRANSDUCTION; VANADIUM COMPOUNDS;

EID: 0031919553     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006853426679     Document Type: Article

References (89)

1. Hunter T: A thousand and one protein kinases. Cell 50: 823-829, 1987
2. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990
3. Pawson T: Protein nodules and signalling networks. Nature 373: 573-580, 1995
4. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Thierfelder WE, Kreider B, Silvennoinen O: Signaling by the cytokine receptor superfamily JAKs and STATS. Trends Biochem Sci 19: 222-227, 1994
5. Roupas P, Herington AC: Postreceptor signaling mechanisms for growth hormone. Trends Endocrinol Metab 5: 154-158, 1994
6. Clark EA, Brugge JS: Integrins and signal transduction pathways: The road taken. Science 268: 233-239, 1995
7. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J: A role for Pyk2 and Src in linking G-protein coupled receptors with MAP kinase activation. Nature 383: 547-550, 1996
8. Fischer EH, Charbonneau H, Tonks N-K: Protein tyrosine phosphatases: A diverse family of intracellular and transmembrane enzymes. Science 253: 401-406, 1991
9. Wallon KM, Dixon JE: Protein tyrosine phosphatases. Annu Rev Biochem 62: 101-120, 1993
10. Fauman EB, Saper MA: Structure and function of the protein tyrosine phosphatases. Trends Biochem Sci 21: 413-417, 1996
11. White MF, Kahn CR: The insulin signaling system. J Biol Chem 269: 1-5, 1994
12. Patti M-E, Sun X-J, Bruening JC, Araki E, Lipes MA, White MF, Kahn CR: 4PS/Insulin receptor substrate (IRS)-2 is the alternative substrate of the insulin receptor in IRS-1-deficient mice. J Biol Chem 270: 24670-24673, 1995
13. Gustafson TA, He W, Craparo A, Schaub CD, O'Neill TJ: Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol Cell Biol 15: 2500-2508, 1995
14. van der Geer P, Wiley S, Ka-Man Lai V, Olivier JP, Gish GD, Stephens R, Kaplan D, Shoelson S, Pawson T: A conserved amino-terminal She domain binds to phosphotyrosine motifs in activated receptors and phosphopeptides. Curr Biol 5: 404-412, 1995
15. Cheatham B, Kahn CR: Insulin action and the insulin signaling network. Endo Rev 16: 117-142, 1995
16. Sun XJ, Crimmins DL, Myers MG, Miralpeix M, White MP: Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol 13: 7418-7428, 1993
17. Macara IG: Vanadium: An element in search of a role. Trends Biochem Sci 5: 92-94, 1980
18. +) ATPase from the cytoplasmic side. Nature Lond 272: 552-554, 1978
19. Nechay BR, Nanninga LB, Nechay PSE, Post RL, Granthan JJ, Macara IG, Kubena LF, Phillips TD, Nielsen FFH: Role of vanadium in biology. Fed Proc 45: 123-132, 1986
20. Stankiewicz PJ, Tracey AS, Crans DC: Inhibition of phosphate-metabolizing enzymes by oxovanadium comples. In: H Sigel, A Sigel (eds). Metal Ions in Biological Systems. Marcel Dekker, New York, 1995, 31: 287-324a
21. Swarup G, Cohen S, Garbers D: Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun 107: 1104-1109, 1982
22. Swarup G, Speeg JKV, Coben S, Garbers DL: Phosphotyrosyl-protein phosphatase of TCRC-2 cells. J Biol Chem 257: 7298-7301, 1982
23. Tolman EL, Barris E, Bums M, Pansini A, Partridge R: Effects of vanadium on glucose metabolism in vitro. Life Sci 25: 1159-1164, 1979
24. +)-ATPase inhibitor. J Biol Chem 255: 5306-5312, 1980
25. Shechter Y, Karlish SJD: Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature 284: 556-558, 1980
26. Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227: 1474-1477, 1985
27. Crans DC: Aqueous chemistry of labile oxovanadates: Relevance to biological studies. Comm Inorganic Chem 16: 1-33, 1994
28. Shaver A, Ng JB, Hall DA, Posner BI: The chemistry of peroxovanadium compounds relevant to insulin mimesis. Mol Cell Biochem 153: 5-15, 1995
29. Shechter Y: Insulin-mimetic effects of vanadate: Possible implications for future treatment of diabetes. Diabetes 39: 1-5, 1990
30. Posner BI, Shaver A, Fantus IG: Insulin mimetic agents: Vanadium and peroxovanadium compounds. In: CJ Bailey, PR Flatt (eds). New Antidiabetic Drugs. Smith-Gordon, London, 1990, pp 107-118
31. Orvig C, Thompson KH, Battell M, McNeill JH: Vanadium compounds as insulin mimics. In: H Sigel, A Sigel (eds). Metal Ions in Biological Systems. Marcel Dekker, New York, 1995, 31: 575-594
32. Brichard SM, Ongemba LN, Henquin JC: Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia 35: 522-527, 1992
33. Tsiani E, Fantus IG: Vanadium compounds: Biological actions and potential as pharmacological agents. Trends Endocrinol Metab 8: 51-58, 1997
34. Brichard SM, Henquin J-C: The role of vanadium in the management of diabetes. Trends Pharmacol Sci 16: 265-270, 1995
35. Kahn CR: Insulin resistance, insulin insensitivity, and insulin unresponsiveness: A necessary distinction. Metabolism 27: 1893-1902, 1978
36. Fantus IG, Ahmad F, Deragon G. Vanadate augments insulin binding and prolongs insulin action in rat adipocytes. Endocrinology 127: 2716-2725, 1990
37. Eriksson JW, Lonnrath P, Smith U: Vanadate increases cell surface insulin binding and improves insulin sensitivity in both normal and insulin-resistant rat adipocytes. Diabetologia 35: 510-516, 1992
38. Brichard SM, Pettier AM, Henquin JC: Long-term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology. 125: 2510-2516, 1989
39. Rossetti L, Laughlin MR: Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84: 892-899, 1989
40. Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR: Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 87: 1286-1294, 1991
41. Fantus IG, Ahmad F, Deragon G: Vanadate augments insulin-stimulated insulin receptor kinase activity and prolongs insulin action in rat adipocytes: Evidence for transduction of amplitude of signaling into duration of response. Diabetes 43: 375-383, 1994
42. Haring HU, Biermann E, Kemmler W: Relation of insulin receptor occupancy and deactivation of glucose transport. Am J Physiol 242: E234-E240, 1982
43. Fantus IG, Kadota S, Deragon G, Foster B, Posner BI: Pervanadate [peroxides of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. Biochemistry 28: 8864-8871, 1989
44. Clark AS, Fagan JM, Mitch WE: Selectivity of insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle. Biochem J 232: 273-276, 1985
45. Foot E, Bliss T, Fernandes L, DaCosta C, Leighton B: The effects of orthovanadate, vanadyl and peroxides of vanadate on glucose metabolism in skeletal muscle preparations in vitro. Mol Cell Biochem 109: 157-162, 1992
46. Tsiani E, Abdullah N, Fantus IG: The insulin-mimetic agents vanadate and pervanadate stimulate glucose but inhibit amino acid uptake. Am J Physiol 272: C156-C162, 1997
47. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Soo Lum B, Shaver A: Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596-4604, 1994
48. Nasmyth K: Viewpoint: Putting the cell cycle in order. Science 274: 1643-1645, 1996
49. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996
50. Klarlund JK: Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine proteins. Cell 41: 707-717, 1985
51. Feldman RA, Lowy DR, Vass WC: Selective potentiation of C-fps/fes transforming activity by a phosphatase inhibitor. Oncogene Res 5: 187-197, 1990
52. Chen Y, Chan TM: Orthovanadate and 2,3-dimethoxy-1,4-naphthoquinone augment growth factor-induced cell proliferation and c-fos gene expression in 3T3-L1 cells. Arch Biochem Biophys 305: 9-16, 1993
53. Wang H, Scott RE: Unique and selective mitogenic effects of vanadate on SV40-transformed cells. Mol Cell Biochem 153: 59-67, 1995
54. Hanauske U, Hanauske A-R, Marshall MH, Muggia VA, Von Hoff DD: Biphasic effect of vanadium salts on in vitro tumor colony growth. Intern J Cell Cloning 5: 170-178, 1987
55. Cruz TF, Morgan A, Min W: In vitro and in vivo antineoplastic effects of orthovanadate. Mol Cell Biochem 153: 161-166, 1995
56. Faure R, Vincent M, Dufour M, Shaver A, Posner BI: Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: Studies on a neuronal and a glial cell line. J Cell Biochem 59: 389-401, 1995
57. Djordjevic C: Antitumor activity of vanadium compounds. In: H Sigel, A Sigel (eds). Metal Ions in Biological Systems. Marcel Dekker Inc., New York, 1995, 31: 595-616
58. Beguinot F, Kahn CR, Moses AC, Smith RJ: Distinct biologically active receptors for insulin, insulin-like growth factor 1, and insulin-like growth factor II in cultured skeletal muscle cells. J Biol Chem 260: 15892-15898, 1985
59. Giorgino F, Smith RJ: Dexamethasone enhances insulin-like growth factor-1 effects on skeletal muscle cell proliferation. Role of specific intracellular signaling pathways. J Clin Invest 96: 1473-1483, 1995
60. Kadota S, Fantus IG, Deragon G, Guyda HJ, Hersh B, Posner BI: Peroxide(s) of vanadium: A novel and potent insulin-mimetic agent which activates the insulin receptor kinase. Biochem Biophys Res Commun 147: 259-266, 1987
61. Skolnik EY, Baker A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis B, Schlessinger J: The function of GRB2 in binding the insulin receptor to ras signaling pathways. Science 260: 1953-1955, 1993
62. Milarski KL, Saltiel AR: Expression of catalytically inactive syp phosphatase in 3T3 cells blocks stimulation of mitogen-activated protein kinase by insulin. J Biol Chem 269: 21239-21243, 1994
63. Xiao S, Rose DW, Sasaoka T, Maegawa H, Burke RT Jr, Roller PP, Shoelson SE, Olefsky JM: Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction. J Biol Chem 269: 21244-21248, 1994
64. Noguchi T, Matozaki T, Horita K, Fujioka Y, Kasuga M. Role of SH-PTP2, a protein tyrosine phosphatase with Src homology 2 domains, in insulin stimulated Ras activation. Mol Cell Biol 14: 6674-6682, 1994
65. Morgan DO: Principles of CDK regulation. Science 374: 131-134, 1995
66. Sebastian B, Kakizuka A, Hunter T: cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc Natl Acad Sci USA 90: 30521-3524, 1993
67. Krek W, DeCaprio JA: Cell synchronization. Meth Enzymol 254: 114-124, 1995
68. Hamaguchi T, Sudo T, Osada H: RK-682, a potent inhibitor of tyrosine phosphatase arrested the mammalian cell cycle progression at G1 phase. FEBS Lett 372: 54-58, 1995
69. D'Onofrio F, Le MQ, Chiasson J-L, Srivastava AK: Activation of mitogen-activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation. FEBS Lett 340: 269-275, 1994
70. Pandey SK, Chiasson JL, Srivastava AK: Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases. Mol Cell Biochem 153: 69-78, 1995
71. S6K are required for insulin but not bisperoxovanadium 1, 10 phenanthroline [bpV(phen)] inhibition of insulin-like growth factor binding protein gene expression. Evidence for MEK-independent activation of mitogen-activated protein kinase by bpV(phen). J Biol Chem 272: 138-145, 1997
72. Sun H, Tonks NK, Bar-Sagi D: Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. Science 266: 285-288, 1994
73. Groom LA, Sneddon AA, Alessi DR, Dowd S, Keyse SM: Differential regulation of the MAP, SAP and RK/p38 kinases by Pystl, a novel cytosolic dual-specificity phosphatase. EMBO J 15: 3621-3632, 1996
74. Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14556, 1993
75. Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-186, 1995
76. Lamphere L, Lienhard GE: Components of signaling pathways for insulin and insulin like growth factor-I in muscle myoblasts and myotubes. Endocrinology 131: 2196-2202, 1992
77. deVries-Smits AMM, Burgering BMT, Leevers SJ, Marshall CJ, Bos JL: Involvement of p2 Iras in activation of extracellular signal-regulated kinase 2. Nature 357: 602-604, 1992
78. Shisheva A, Shechter Y: Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. J Biol Chem 268: 6463-6469, 1993
79. Shisheva A, Shechter Y: Mechanism of pervanadate stimulation and potentiation of insulin-activated glucose transport in rat adipocytes: Dissociation from vanadate effect. Endocrinology 133: 1562-1568, 1993
80. Huyer G, Liu S, Kelly J, Moffat J, Pryette P, Kennedy B, Tsaprailis G, Gesser MJ, Ramachandran C: Mechanism of inhibition of protein-tyrosine phosphatase by vanadate and pervanadate. J Biol Chem 272: 843-851, 1997
81. Tsiani E, Sorisky A, Fantus IG: Vanadate and pervanadate increase glucose uptake in L6 skeletal muscle cells by a mechanism independent of PI3K. 10th International Congress of Endocrinology. Program and Abstracts, Vol. 11: OR66-6, 1997
82. Ida M, Imai K, Hashimoto S, Kawashima H: Pervanadate stimulation of wortmannin-sensitive and -resistant 2-deoxyglucose transport in adipocytes. Biochem Pharmacol 51: 1061-1067, 1996
83. Folli F, Saad MJA, Backer JM, Kahn CR: Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest 92: 1787-1794, 1993
84. Goodyear U, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL: Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95: 2195-2204, 1995
85. Bjornholm M, Kawano Y, Lehtihet M, Zierath JR: Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes 46: 524-527, 1997
86. Goldfine AB, Simonson DC, Folli F, Patti M-E, Kahn CR: In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem 153: 217-231, 1995
87. Cohen N, Halberstam M, Shlimovich, Chang CJ, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95: 2501-2509, 1995
88. DeFronzo RA, Ferrannini E: Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194, 1991
89. Tlsty T, Briot A, Poulose B: Analysis of cell cycle checkpoint status in mammalian cells. Meth Enzymol 254: 125-133, 1995